Introducción y objetivos Los programas de telemedicina entre clínico y paciente se han desarrollado con fuerza durante la pandemia de enfermedad por COVID-19, pero no hay datos de experiencias entre clínicos. Nuestro objetivo es analizar el impacto de la pandemia por COVID-19 en la actividad y resultados en salud de un programa de consulta electrónica universal (e-consulta) para todas las derivaciones de pacientes entre médicos de atención primaria y el Servicio de Cardiología de nuestra área. Métodos Analizamos mediante regresión logística a 25.121 pacientes con al menos una e-consulta entre 2018 y 2021 realizada con el Servicio de Cardiología de nuestra área sanitaria. También se realizó el análisis de regresión logística del impacto de la pandemia por COVID-19 sobre la resolución de la e-consulta y tiempo de espera de la atención, hospitalizaciones y mortalidad, tomando como referencia las consultas realizadas durante 2018. Resultados Observamos que una menor demora en la atención y resolución de la e-consulta (sin necesidad de atención presencial) se asociaba a un mejor pronóstico. Los períodos de pandemia COVID-19 presentaron similares resultados a los del 2018. Conclusiones Los resultados de nuestro estudio muestran una significativa reducción de las derivaciones a través de e-consulta durante el primer año de la pandemia por COVID-19 con recuperación posterior de la demanda asistencial sin que los períodos de pandemia se asociasen con peores resultados en salud. La reducción del tiempo de demora de resolución de la e-consulta y el grupo sin necesidad de consulta presencial se asociaron a un mejor pronóstico (AU)
Blackground and objective Virtual healthcare models, usually between healthcare professionals and patients, have developed strongly during the coronavirus disease 2019 (COVID-19) pandemic, but there are not data of models between clinicians. Our objective is to analyse the impact of the COVID-19 pandemic on the activity and health outcomes of the universal e-consultation program for patient referrals between primary care physicians and the Cardiology Department in our area. Methods Patients with at least one e-consultation between 2018 and 2021 were selected. We analysed the impact of the COVID-19 pandemic on activity and waiting time for care, hospitalizations and mortality, taking as a reference the consultations carried out during 2018. Results We analysed 25,121 patients. Through logistic regression analysis, it was observed that a shorter delay in care and resolution of the e-consultation without the need for face-to-face care were associated with a better prognosis. The COVID-19 pandemic periods (2019-2020 and 2020-2021) were not associated with worse health outcomes compared to 2018. Conclusions The results of our study show a significant reduction in e-consult referrals during the first year of the COVID-19 pandemic with a subsequent recovery in the demand for care without the pandemic periods being associated with worse outcomes. The reduction in the time elapsed for solving the e-consult and no need for in-person visit were associated with better outcomes (AU)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Remote Consultation/statistics & numerical data , Primary Health Care/statistics & numerical data , Telecardiology , Coronavirus Infections/epidemiology , Pandemics , Logistic Models , Spain
Blackground and objective: Virtual healthcare models, usually between healthcare professionals and patients, have developed strongly during the coronavirus disease 2019 (COVID-19) pandemic, but there are not data of models between clinicians. Our objective is to analyse the impact of the COVID-19 pandemic on the activity and health outcomes of the universal e-consultation program for patient referrals between primary care physicians and the Cardiology Department in our area. Methods: Patients with at least one e-consultation between 2018 and 2021 were selected. We analysed the impact of the COVID-19 pandemic on activity and waiting time for care, hospitalizations and mortality, taking as a reference the consultations carried out during 2018. Results: We analysed 25,121 patients. Through logistic regression analysis, it was observed that a shorter delay in care and resolution of the e-consultation without the need for face-to-face care were associated with a better prognosis. The COVID-19 pandemic periods (2019-2020 and 2020-2021) were not associated with worse health outcomes compared to 2018. Conclusions: The results of our study show a significant reduction in e-consult referrals during the first year of the COVID-19 pandemic with a subsequent recovery in the demand for care without the pandemic periods being associated with worse outcomes. The reduction in the time elapsed for solving the e-consult and no need for in-person visit were associated with better outcomes.
BACKGROUND AND OBJECTIVE: Virtual healthcare models, usually between healthcare professionals and patients, have developed strongly during the coronavirus disease 2019 (COVID-19) pandemic, but there are no data corresponding to models between clinicians. An analysis was made of the impact of the COVID-19 pandemic upon the activity and health outcomes of the universal e-consultation program for patient referrals between primary care physicians and the Cardiology Department in our healthcare area. METHODS: Patients with at least one e-consultation between 2018 and 2021 were selected. We analyzed the impact of the COVID-19 pandemic upon activity and waiting time for care, hospitalizations and mortality, taking as reference the consultations carried out during 2018. RESULTS: A total of 25,121 patients were analyzed. Logistic regression analysis showed a shorter delay in care and resolution of the e-consultation without the need for face-to-face care to be associated to a better prognosis. The COVID-19 pandemic periods (2019-2020 and 2020-2021) were not associated to poorer health outcomes compared to 2018. CONCLUSIONS: The results of our study show a significant reduction in e-consultation referrals during the first year of the COVID-19 pandemic, with a subsequent recovery in the demand for care, and without the pandemic periods being associated to poorer outcomes. The reduction in time elapsed for resolving the e-consultations and no need for face-to-face visits were associated to improved outcomes.
COVID-19 , Cardiologists , General Practitioners , Remote Consultation , Humans , COVID-19/epidemiology , Pandemics , Referral and Consultation
Objetivo: Analizar el impacto del inicio del tratamiento con la polipíldora-cardiovascular (CV) del Centro Nacional de Investigaciones Cardiovasculares (CNIC-Ferrer), en las cifras de presión arterial (PA) y colesterol ligado a lipoproteínas de baja densidad (LDL), de los pacientes de nuestra área sanitaria que previamente recibían dosis equipotentes de estatinas y antihipertensivos. Material y métodos: Se registraron todos los pacientes de nuestra área sanitaria (Santiago de Compostela) que a 31 de diciembre de 2019 tenían una prescripción activa de polipíldora-CV (CNIC-Ferrer), desde el 16 de enero de 2015. La fecha índice fue la fecha de inicio de prescripción de polipíldora-CV, y se analizaron los fármacos que previamente recibía el paciente para dislipemia e hipertensión arterial, clasificándose por equipotencias con atorvastatina y ramipril. Se analizó mediante la prueba t-Student para muestras apareadas las variaciones de colesterol LDL y PA. Resultados: Analizamos 547 pacientes con una edad media de 71,5±11,5 años y la mayoría varones (60,6%). Observamos un descenso del colesterol LDL (−10,6 [IC95%: −7,0, −14,3], p<0,001) en los pacientes (n=471) que iniciaron la polipíldora-CV con dosis previas equipotentes de atorvastatina. Documentamos una reducción de la PA sistólica (−3,7 [IC95%: −0,4, −6,9], p=0,029) en los pacientes (n=360) con inicio a partir de dosis equipotentes de ramipril. En 88 pacientes, el inicio de la polipíldora-CV se hizo a partir de dosis equipotentes de atorvastatina y ramipril observándose un descenso del colesterol LDL (−8,7 [IC95%: −3,8, −13,6], p=0,001) y de la PA sistólica (−3,6 [IC95%: −7,8, 0,5], p=0,085). Conclusiones: El inicio del tratamiento con la polipíldora-CV, en pacientes que previamente recibían tratamientos equipotentes de atorvastatina y ramipril, se asoció a una mayor reducción del colesterol LDL y la PA sistólica (AU)
Objective: This work aims to analyze the impact of Spain's National Center for Cardiovascular Research (CNIC-Ferrer)s cardiovascular (CV)-polypill on blood pressure (BP) and low-density lipoprotein cholesterol (cLDL) levels in patients in our healthcare area who previously took equipotent doses of statins and antihypertensives. Material and methods: All patients in our healthcare area (Santiago de Compostela, Spain) who, as of December 31, 2019, had an active prescription for the CV-polypill (CNIC-Ferrer) since January 16, 2015 were registered. The index date was the start date of the CV-polypill prescription. The drugs the patient had previously received for dyslipidemia and hypertension were analyzed, classifying them by their equivalent potency to atorvastatin and ramipril. Changes in cLDL and BP were analyzed by means of Student's t-test for paired samples. Results: We analyzed 547 patients with a mean age of 71.5±11.5 years. The majority were men (60.6%). We observed a decrease in cLDL (−10.6 [95% CI: −7.0, −14.3], p<.001) in patients who started taking the CV-polypill who had previously taken equally potent doses of atorvastatin (n=471). We documented a reduction in systolic BP (−3.7 [95% CI: −0.4, −6.9], p=.029) in patients who had previously taken equally potent doses of ramipril (n=360). In 88 patients, the CV-polypill was started via equally potent doses of atorvastatin and ramipril, with a decrease in cLDL (−8.7 [95% CI: −3.8, −13.6], p=.001) and systolic BP (−3.6 [95% CI: −7.8, 0.5], p=.085). Conclusions: The initiation of treatment with the CV-polypill in patients who previously received equally potent treatment with atorvastatin and ramipril was associated with a greater reduction in cLDL and systolic BP (AU)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Antihypertensive Agents/therapeutic use , Cardiovascular Diseases/prevention & control , Hydroxymethylglutaryl CoA Reductases/therapeutic use , Drug Therapy, Combination , Treatment Adherence and Compliance , Risk Factors
BACKGROUND: The efficacy and safety of acetylsalicylic acid (ASA) prophylaxis for the primary prevention of atherosclerotic cardiovascular disease (ACVD) remain controversial in people with diabetes (DM) without ACVD, because the possible increased risk of major bleeding could outweigh the potential reduction in the risk of mortality and of major adverse cardiovascular events (MACE) considered individually or together. OBJECTIVE: To evaluate the overall risk-benefit of ASA prophylaxis in primary prevention in people with DM and to compare the recommendations of the guidelines with the results of the meta-analyses (MA) and systematic reviews (SR). MATERIAL AND METHODS: We searched Medline, Google Scholar, Embase, and the Cochrane Library for SR and MA published from 2009 to 2020 which compared the effects of ASA prophylaxis versus placebo or control followed up for at least one year in people with DM without ACVD. Heterogeneity among the randomized clinical trials (RCT) included in the SR and MA was assessed. Cardiovascular outcomes of efficacy (all-cause mortality [ACM], cardiovascular mortality [CVM], myocardial infarction [MI], stroke and MACE) and of safety (major bleeding events [MBE], major gastrointestinal bleeding events [MGIBE], and intracranial and extracranial bleeding) were shown. RESULTS: The recommendations of 12 guidelines were evaluated. The results of 25 SR and MA that included a total of 20 RCT were assessed. None of the MA or SR showed that ASA prophylaxis decreased the risk of ACM, CVM or MI. Only two of the 19 SR and MA that evaluated ischemic stroke showed a decrease in the stroke risk (mean 20.0% [SD±5.7]), bordering on statistical significance. Almost half of the MA and SR showed, bordering on statistical significance, a risk reduction for the MACE composite endpoint (mean 10.5% [SD±3.3]). The significant increases in MGIBE risk ranged from 35% to 55%. The significant increases in the risk of MBE and extracraneal bleeding were 33.4% (SD±14.9) and 54.5% (SD±0.7) respectively. CONCLUSION: The overall risk-benefit assessment of ASA prophylaxis in primary prevention suggests that it should not be applied in people with DM.
Diabetes Mellitus , Myocardial Infarction , Stroke , Aspirin/adverse effects , Diabetes Mellitus/drug therapy , Hemorrhage/chemically induced , Humans , Myocardial Infarction/drug therapy , Primary Prevention
Introducción y objetivos: Muchos sistemas sanitarios han iniciado programas de consulta electrónica, aunque poco se conoce de su impacto en acceso, seguridad y satisfacción. El objetivo de este estudio es evaluar el impacto clínico de la puesta en marcha de un modelo de atención ambulatoria que incluye una consulta electrónica (e-consulta) inicial comparándolo con un modelo presencial de acto único. Métodos: Se seleccionó a pacientes con al menos 1 consulta al servicio de cardiología entre 2010 y 2019. Mediante un modelo de regresión de series temporales interrumpidas, se analizó el impacto de la incorporación de la e-consulta en el modelo asistencial (iniciado en 2013), evaluando: tiempo de espera de la atención, asistencias a urgencias, ingresos hospitalarios y mortalidad. Resultados: Se analizó a 47.377 pacientes: el 61,9% de ellos atendidos incorporando la e-consulta y el 38,1% en el modelo de consulta presencial de acto único. La mediana [intervalo intercuartílico] de la demora a la atención en el modelo de e-consulta, 7 [5-13] días, fue menor que en el modelo presencial: 33 [14-81] días (p<0,001). El modelo de regresión para series temporales interrumpidas mostró que la incorporación de la e-consulta aporta una disminución muy importante en la demora de la atención, que se mantiene en torno a los 9 días, aunque con ligeras oscilaciones. Los pacientes valorados vía e-consulta tuvieron menos ingresos hospitalarios (el 0,9 frente al 1,2%; p=0,0017) y mortalidad (el 2,5 frente al 3,9%; p<0,001). Conclusiones: Un programa de atención ambulatoria que incluye una e-consulta ha mostrado importantes reducciones en los tiempos de espera y es un modelo seguro, con menores tasas de ingresos hospitalarios y mortalidad en el primer año (AU)
Introduction and objectives: Many health systems have initiated electronic consultation (e-consultation) programs, although little is known about their impact on accessibility, safety, and satisfaction. The aim of this study was to assess the clinical impact of the implementation of an outpatient care model that includes an initial e-consultation and to compare it with a one-time face-to-face consultation model. Methods: We selected patients who visited the cardiology service at least once between 2010 and 2019. Using an interrupted time series regression model, we analyzed the impact of incorporating e-consultation into the health care model (started in 2013), and evaluated waiting times, emergency services, hospital admissions, and mortality. Results: We analyzed 47 377 patients: 61.9% were attended in e-consultation and 38.1% in one-time face-to-face consultations. The waiting time for care was shorter in the e-consultation model (median [IQR]: 7 [5-13] days) than in the face-to-face model (median [IQR]: 33 [14-81] days), P<.001. The interrupted time series regression model showed that the introduction of e-consultation substantially decreased waiting times, which held steady at around 9 days, although with slight oscillations. Patients evaluated via e-consultation had fewer hospital admissions (0.9% vs 1.2%, P=.0017) and lower mortality (2.5% vs 3.9%, P<.001). Conclusions: An outpatient care program that includes an e-consultation reduced waiting times significantly and was safe, with a lower rate of hospital admissions and mortality in the first year (AU)
Humans , Male , Female , Adult , Middle Aged , Aged , Remote Consultation , Telecardiology , Regression Analysis , Patient Satisfaction
OBJECTIVE: This work aims to analyze the impact of Spain's National Center for Cardiovascular Research (CNIC-Ferrer)'s cardiovascular (CV)-polypill on blood pressure (BP) and low-density lipoprotein cholesterol (cLDL) levels in patients in our healthcare area who previously took equipotent doses of statins and antihypertensives. MATERIAL AND METHODS: All patients in our healthcare area (Santiago de Compostela, Spain) who, as of December 31, 2019, had an active prescription for the CV-polypill (CNIC-Ferrer) since January 16, 2015 were registered. The index date was the start date of the CV-polypill prescription. The drugs the patient had previously received for dyslipidemia and hypertension were analyzed, classifying them by their equivalent potency to atorvastatin and ramipril. Changes in cLDL and BP were analyzed by means of Student's t-test for paired samples. RESULTS: We analyzed 547 patients with a mean age of 71.5 ± 11.5 years. The majority were men (60.6%). We observed a decrease in cLDL (-10.6 [95% CI: -7.0, -14.3], p < 0.001) in patients who started taking the CV-polypill who had previously taken equally potent doses of atorvastatin (n = 471). We documented a reduction in systolic BP (-3.7 [95% CI: -0.4, -6.9], p = 0.029) in patients who had previously taken equally potent doses of ramipril (n = 360). In 88 patients, the CV-polypill was started via equally potent doses of atorvastatin and ramipril, with a decrease in cLDL (-8.7 [95% CI: -3.8, -13.6], p = 0.001) and systolic BP (-3.6 [95% CI: -7.8, 0.5], p = 0.085). CONCLUSIONS: The initiation of treatment with the CV-polypill in patients who previously received equally potent treatment with atorvastatin and ramipril was associated with a greater reduction in cLDL and systolic BP.
Cardiovascular Diseases , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Aged , Aged, 80 and over , Antihypertensive Agents/therapeutic use , Cardiovascular Diseases/prevention & control , Drug Combinations , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Male , Medication Adherence , Middle Aged , Risk Factors
OBJECTIVE: To analyse the impact of a management plan for the diabetes process on the level of control of HbA1c and the rate of hypoglycaemia. MATERIAL AND METHODS: The Health Area had a catchment population of 446,603. An anti-diabetic drug prescription (29,705 patients) was used to select diabetic patients. The variables recorded were: percentage of patients with HbA1c <8% and the hypoglycaemia rate before and after implementation of the quality program. RESULTS: The prevalence of diabetes was 11.8%, with 71.3% of them receiving some pharmacological treatment. In the year 2016, in the Integrated Health Area of Santiago de Compostela (Spain), 59.6% (95% CI: 57.9% -61.2%) of the patients had an HbA1c of less than 8%. After the implementation of the quality program, there was an increase in the number of controlled patients, reaching 63.6% (IRQ: 16.0%) in 2017, and 63.8% (95% CI: 62.5% - 65.2%) in 2018. The annual rate of hypoglycaemia increased non-significantly from 2.8 (95% CI: 2.22-3.35) in 2016, to 2.94 (95% CI: 2.35-2.35) in 2017 (P=.083), and 3.0 (95% CI: 2.44-3.56) in 2018 (P=.399). CONCLUSIONS: The implementation of the diabetes process management program enabled the level of control of HbA1c to be improved, as well as increase the percentage of patients who undergo regular check-ups, without increasing hypoglycaemia.
Diabetes Mellitus, Type 2 , Hypoglycemia , Glycated Hemoglobin/analysis , Humans , Hypoglycemia/chemically induced , Hypoglycemia/epidemiology , Prevalence , Spain/epidemiology
Parece necesario que las sociedades científicas de AP, ámbito en el cual la prevalencia de HTA es considerable, evalúen periódicamente las directrices internacionales para el manejo de la HTA, sobre todo ante recomendaciones dispares que dificultan la toma de decisiones, en la práctica clínica diaria. El presente documento tiene como objetivo analizar los cambios y novedades propuestos en la guía del American College of Cardiology y de la American Heart Association (ACC/AHA 2017) y en la guía de la European Society of Cardiology y de la European Society of Hypertension (ESC/ESH 2018). Además, analizar las posibles diferencias, limitaciones y su aplicabilidad a la AP de España. En definitiva, se trata de extraer la información más relevante disponible y pertinente, e integrarla para homogeneizar la asistencia al paciente hipertenso desde una perspectiva crítica, pero también razonada. Las discrepancias entre ambas GPC en aspectos tan trascendentales como el manejo de la enfermedad obligan a la recopilación y análisis crítico de la información que nos permita tomar posición como sociedad científica, interesada en trasladar a todos los médicos de AP las recomendaciones más relevantes, pero a la vez sensatas, de ambas GPC
The Scientific Societies of Primary Care, being the area in which there is a considerable prevalence of Arterial Hypertension (AHT), need to periodically evaluate the international guidelines for its management. This is particularly relevant when disparate guidelines make it difficult to make decisions in daily clinical practice. The present document has as its aim to analyse the changes and new developments proposed in the guidelines of the American College of Cardiology and the American Heart Association (ACC/AHA 2017), as well as in the guidelines of the European Society of Cardiology and European Society of Hypertension (ESC/ESH 2018). An analysis will be made of any differences, limitations, and their applicability to Primary Care in Spain. Finally, the most relevant available and appropriate information is extracted and integrated in order to homogenise the care of the hypertensive patient, from a critical, but also a reasoned, perspective. The discrepancies between the recommendations in such essential aspects as the management of the disease, require the compiling and critical analysis of the information that enables us as scientific society, interested in providing all PC physicians with the most relevant, and at the same time, sensible, recommendations of all the guidelines
Humans , Hypertension/therapy , Practice Guidelines as Topic , Primary Health Care/organization & administration , Physicians, Primary Care/organization & administration , Societies, Medical , Spain
The Scientific Societies of Primary Care, being the area in which there is a considerable prevalence of Arterial Hypertension (AHT), need to periodically evaluate the international guidelines for its management. This is particularly relevant when disparate guidelines make it difficult to make decisions in daily clinical practice. The present document has as its aim to analyse the changes and new developments proposed in the guidelines of the American College of Cardiology and the American Heart Association (ACC/AHA 2017), as well as in the guidelines of the European Society of Cardiology and European Society of Hypertension (ESC/ESH 2018). An analysis will be made of any differences, limitations, and their applicability to Primary Care in Spain. Finally, the most relevant available and appropriate information is extracted and integrated in order to homogenise the care of the hypertensive patient, from a critical, but also a reasoned, perspective. The discrepancies between the recommendations in such essential aspects as the management of the disease, require the compiling and critical analysis of the information that enables us as scientific society, interested in providing all PC physicians with the most relevant, and at the same time, sensible, recommendations of all the guidelines.
Hypertension/therapy , Practice Guidelines as Topic , Primary Health Care/organization & administration , Humans , Physicians, Primary Care/organization & administration , Societies, Medical , Spain
Objetivo. Conocer la evolución temporal del control del tiempo en rango terapéutico de los pacientes con tiempo en rango terapéutico insuficiente. Material y métodos. Se plantea un estudio longitudinal a partir de una muestra no seleccionada de todos los pacientes atendidos en un centro de salud a lo largo de 3 años (2011-2013). Se seleccionaron pacientes que recibieran anticoagulación con antivitamina K al menos durante 6 meses por una fibrilación auricular no valvular, obteniendo una muestra final de 130 pacientes. Resultados. El 53,1% eran varones, con una edad media de 77 ± 1,5 años. La prevalencia de hipertensión y de diabetes mellitus fue del 90% y del 33,8% respectivamente, y el 11,5% y el 14,6% había presentado una insuficiencia cardíaca o un accidente cerebrovascular. El número medio de fármacos consumidos por los pacientes fue de 7,6 ± 0,6. La prevalencia del insuficiente control del tiempo en rango terapéutico, calculado por Rosendaal, fue del 60,2% en 2011, del 54,2% en 2010 y del 43,4% en 2012. Analizando el comportamiento del tiempo en rango terapéutico en pacientes con insuficiente control en el primer trimestre de seguimiento, se observó que se mantendría bajo en los años siguientes: 69,7 vs. 55%, p = 0,0005, en 2011; 71,9 vs. 59,3%, p = 0,0015 en 2012; y 74,7 vs. 60%, p < 0,0005 en 2013. Conclusiones. Nuestro estudio muestra que los pacientes con tiempo en rango terapéutico insuficiente presentan una tendencia a mantenerse en el mal control, por lo que planteamos la necesidad de tomar precozmente las decisiones clínicas en los pacientes anticoagulados atendiendo al pronóstico y costes económicos de la fibrilación auricular y su tratamiento (AU)
Objective. To determine the temporal trend in poorly-controlled anticoagulated patients. Material and methods. A longitudinal study was conducted on a non-unselected sample of all patients seen in a health centre over a period of 3 years (2011-2013). Patients who received anti-vitamin K anticoagulation for at least 6 months due to non-valvular atrial fibrillation were selected, obtaining a final sample of 130 patients. Results. The mean age of the sample was 77.0 ± 1.5 years and 53.1% were male. The prevalence of hypertension and diabetes mellitus was 90% and 33.8%, respectively, and 11.5% and 14.6% had had heart failure or a stroke, respectively. The mean number of medications taken by patients was 7.6 ± 0.6. The prevalence of insufficient control of time in therapeutic range, calculated by Rosendaal, was 60.2% in 2011, 54.2% in 2010, and 43.4% in 2012. On analysing the time in the therapeutic range in patients with impaired control in the first quarter of follow-up, it was observed to remain low in subsequent years: 69.7% vs 55%, P = .0005, in 2011; 71.9% vs 59.3%, P = .0015 in 2012; and 74.7% vs 60%, P = .0005 in 2013. Conclusions. Our study shows that patients with inadequate time in therapeutic range have a tendency to stay in poor control, suggesting the need for early clinical decisions in patients on anticoagulants, taking into account the prognosis and economic costs of atrial fibrillation and treatment (AU)
Humans , Male , Female , Aged , Anticoagulants/pharmacology , Anticoagulants/therapeutic use , Primary Health Care/methods , Vitamin K/therapeutic use , Drug and Narcotic Control/methods , Follow-Up Studies , Longitudinal Studies , Heart Failure/complications , Heart Failure/prevention & control , Stroke/prevention & control , Atrial Fibrillation/complications , Retrospective Studies
OBJECTIVE: To determine the temporal trend in poorly-controlled anticoagulated patients. MATERIAL AND METHODS: A longitudinal study was conducted on a non-unselected sample of all patients seen in a health centre over a period of 3 years (2011-2013). Patients who received anti-vitamin K anticoagulation for at least 6 months due to non-valvular atrial fibrillation were selected, obtaining a final sample of 130 patients. RESULTS: The mean age of the sample was 77.0±1.5 years and 53.1% were male. The prevalence of hypertension and diabetes mellitus was 90% and 33.8%, respectively, and 11.5% and 14.6% had had heart failure or a stroke, respectively. The mean number of medications taken by patients was 7.6±0.6. The prevalence of insufficient control of time in therapeutic range, calculated by Rosendaal, was 60.2% in 2011, 54.2% in 2010, and 43.4% in 2012. On analysing the time in the therapeutic range in patients with impaired control in the first quarter of follow-up, it was observed to remain low in subsequent years: 69.7% vs 55%, P=.0005, in 2011; 71.9% vs 59.3%, P=.0015 in 2012; and 74.7% vs 60%, P=.0005 in 2013. CONCLUSIONS: Our study shows that patients with inadequate time in therapeutic range have a tendency to stay in poor control, suggesting the need for early clinical decisions in patients on anticoagulants, taking into account the prognosis and economic costs of atrial fibrillation and treatment.
Anticoagulants/therapeutic use , Atrial Fibrillation/drug therapy , Primary Health Care , Aged , Atrial Fibrillation/complications , Diabetes Mellitus/epidemiology , Female , Follow-Up Studies , Heart Failure/epidemiology , Humans , Hypertension/epidemiology , Longitudinal Studies , Male , Retrospective Studies , Stroke/epidemiology , Time Factors , Vitamin K/antagonists & inhibitors
Sphenoidal sinusitis is an uncommon pathology potentially dangerous condition, that we can find in young population. Clinically it is very difficult to diagnose because of its nonspecific symptoms, but cranial computer tomography confirms the diagnosis. The most cases were treated with antibiotics and recovered completely. We present a young man with isolated sphenoidal sinusitis who was managed in our medical centre, and a review of the literature.
Sphenoid Sinusitis/diagnostic imaging , Adult , Humans , Male , Tomography, X-Ray Computed
La sinusitis esfenoidal es una patología muy poco frecuente y potencialmente muy peligrosa, que podemos encontrar en la población más joven. Clínicamente es muy difícil el diagnóstico porque los datos clínicos son inespecíficos, pero el estudio por tomografía axial computarizada (TAC) craneal confirma el diagnóstico. La mayoría de los casos son tratados con antibióticos y se recuperan completamente. Presentamos un caso de sinusitis esfenoidal aislada en paciente joven, que nosotros tratamos en nuestro centro, y una revisión de la literatura
Sphenoidal sinusitis is an uncommon pathology potencially dange condition, what we can find in young population. Clinically it is very difficult the diagnosis because of its nonspecific symptoms, but cranial computer tomography proves the diagnosis. The most cases were trated with antbiotics and recovered completely. We present a young-man with isolated sphenoidal sinusitis who were managed in our medical centre, and a review the literature
Male , Adult , Humans , Sphenoid Sinusitis , Tomography, X-Ray Computed
El priapismo es una urgencia urológica poco frecuente que puede estar en relación con dos mecanismos fisiopatológicos claramente diferenciados: obstrucción de la salida venosa de los cuerpos cavernosos(priapismo venooclusivo) o bien por la llegada a aquéllos de un exceso de flujo arterial (priapismo arterial). En el abordaje inicial es fundamental distinguir si nos enfrentamos a un tipo u otro: el primero, mucho más frecuente, requiere una actuación urgente ya que, a medida que pasen las horas, se asociará a un mayor riesgo de disfunción eréctil permanente, mientras que el segundo, al no provocar isquemia, permite diferir el tratamiento (AU)
Male , Humans , Priapism/etiology , Priapism/diagnosis , Arterial Occlusive Diseases/complications , Angiography , Priapism , Priapism/therapy
